The price target is the mean estimate from the 10 research brokerages that recently issued reports on the firm. On a scale of one to five, with one representing a strong buy and five representing a strong sell, the equity is ranked 1.67 based on broker recommendations. In the long term, analysts have estimated a consensus mean earnings per share of $1.09 for the current year, according to the report.
More articles on devices:
Symmetry Medical to close Indiana orthopedic implant facility
NuVasive CEO resigns after compliance investigation — 5 things to know
Orthofix stock gains big — 14%: 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
